1. Home
  2. SPCE vs IKT Comparison

SPCE vs IKT Comparison

Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

HOLD

Current Price

$3.77

Market Cap

207.3M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

181.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCE
IKT
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.3M
181.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SPCE
IKT
Price
$3.77
$1.66
Analyst Decision
Hold
Buy
Analyst Count
6
2
Target Price
$9.22
$4.00
AVG Volume (30 Days)
5.2M
499.5K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,661,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,656.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$1.33
52 Week High
$6.77
$3.49

Technical Indicators

Market Signals
Indicator
SPCE
IKT
Relative Strength Index (RSI) 52.52 57.62
Support Level $2.92 $1.52
Resistance Level $4.57 $1.67
Average True Range (ATR) 0.32 0.11
MACD -0.03 0.02
Stochastic Oscillator 49.96 65.91

Price Performance

Historical Comparison
SPCE
IKT

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: